QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Last time updated on 25/10/2020